PDGF-BB Protects Mitochondria from Rotenone in T98G Cells

Neurotoxicity Research

Volumn 27, Issue 4, 2015, Pages 355-367

  Cabezas, Ricardo ^a   Avila, Marcos Fidel ^a   González, Janneth ^a   El Bachá, Ramon Santos ^b   Barreto, George E ^a  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Mitochondria; Neuroprotection; PDGF BB; Reactive oxygen species; Rotenone

Indexed keywords

PLATELET DERIVED GROWTH FACTOR BB; REACTIVE OXYGEN METABOLITE; ROTENONE; PLATELET DERIVED GROWTH FACTOR B; PLATELET-DERIVED GROWTH FACTOR BB;

ARTICLE; BRAIN MITOCHONDRION; CELL DAMAGE; CELL PROTECTION; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRIAL VOLUME; NEUROPROTECTION; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ASTROCYTE; CELL SURVIVAL; DRUG EFFECTS; METABOLISM; MITOCHONDRION; TUMOR CELL LINE;

ANIMALIA;

ASTROCYTES; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS C-SIS; REACTIVE OXYGEN SPECIES; ROTENONE;

EID: 84926350993     PISSN: 10298428     EISSN: 14763524     Source Type: Journal    
DOI: 10.1007/s12640-014-9509-5     Document Type: Article

References (57)

1. Andrae J, Gallini R, Betsholtz C (2008) Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22:1276–1312. doi:10.1101/gad.1653708
2. Arduino DM, Esteves AR, Silva DF, Martins-Branco D, Santos D, Pimentel DF, Cardoso SM (2011) Therapeutic intervention at cellular quality control systems in Alzheimer’s and Parkinson’s diseases. Curr Pharm Des 17:3446–3459
3. Avila Rodriguez M, Garcia-Segura LM, Cabezas R, Torrente D, Capani F, Gonzalez J, Barreto GE (2014) Tibolone protects T98G cells from glucose deprivation. J Steroid Biochem Mol Biol 144PB:294–303. doi:10.1016/j.jsbmb.2014.07.009
4. Avila-Gomez IC, Velez-Pardo C, Jimenez-Del-Rio M (2010) Effects of insulin-like growth factor-1 on rotenone-induced apoptosis in human lymphocyte cells. Basic Clin Pharmacol Toxicol 106:53–61. doi:10.1111/j.1742-7843.2009.00472.x
5. Bankhead P (2013) Analyzing fluorescence microscopy images with ImageJ. Nikon Imaging Center, Heidelberg University, Queen’s University Belfast
6. Barreto GE, Gonzalez J, Torres Y, Morales L (2011) Astrocytic-neuronal crosstalk: implications for neuroprotection from brain injury. Neurosci Res 71:107–113. doi:10.1016/j.neures.2011.06.004
7. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 3:1301–1306. doi:10.1038/81834
8. Cabezas R, El-Bacha RS, Gonzalez J, Barreto GE (2012) Mitochondrial functions in astrocytes: neuroprotective implications from oxidative damage by rotenone. Neurosci Res 74:80–90. doi:10.1016/j.neures.2012.07.008
9. Cabezas R et al (2014) Astrocytic modulation of blood brain barrier: perspectives on Parkinson’s disease. Front Cell Neurosci 8:211. doi:10.3389/fncel.2014.00211
10. Cao Q, Wei LR, Lu LL, Zhao CL, Zhao HY, Yang H (2007) Astrocytes protect MN9D neuronal cells against rotenone-induced oxidative stress by a glutathione-dependent mechanism. Sheng Li Xue Bao 59:253–259
11. Chaturvedi RK, Beal MF (2013) Mitochondria targeted therapeutic approaches in Parkinson’s and Huntington’s diseases. Mol Cell Neurosci 55:101–114. doi:10.1016/j.mcn.2012.11.011
12. Cheng B, Mattson MP (1995) PDGFs protect hippocampal neurons against energy deprivation and oxidative injury: evidence for induction of antioxidant pathways. J Neurosci 15:7095–7104
13. de Joannon AC et al (2000) Adenosine triphosphate affects interleukin -1beta release by T98G glioblastoma cells through a purinoceptor-independent mechanism. Neurosci Lett 285:218–222
14. de Oliveira DM et al (2011) Paullinia cupana Mart. var. sorbilis protects human dopaminergic neuroblastoma SH-SY5Y cell line against rotenone-induced cytotoxicity. Hum Exp Toxicol 30:1382–1391. doi:10.1177/0960327110389837
15. de Oliveria DM et al (2009) Cytoprotective effect of Valeriana officinalis extract on an in vitro experimental model of Parkinson disease. Neurochem Res 34:215–220. doi:10.1007/s11064-008-9749-y
16. Dhillon AS, Tarbutton GL, Levin JL, Plotkin GM, Lowry LK, Nalbone JT, Shepherd S (2008) Pesticide/environmental exposures and Parkinson’s disease in East Texas. J Agromedicine 13:37–48. doi:10.1080/10599240801986215
17. Dick FD (2006) Parkinson’s disease and pesticide exposures. Br Med Bull 79–80:219–231. doi:10.1093/bmb/ldl018
18. Falk T, Zhang S, Sherman SJ (2009) Vascular endothelial growth factor B (VEGF-B) is up-regulated and exogenous VEGF-B is neuroprotective in a culture model of Parkinson’s disease. Mol Neurodegener 4:49. doi:10.1186/1750-1326-4-49
19. Gasque P et al (1996) Identification and characterization of complement C3 receptors on human astrocytes. J Immunol 156:2247–2255
20. Giffard R, Ouyang Y (2004) Effect of overexpression of protective genes on mitochondrial function of stressed astrocytes. J Bioenerg Biomembr 36:313–315. doi:10.1023/B:JOBB.0000041760.23917.e1490847
21. Gosslau A, Dittrich W, Willig A, Jaros PP (2001) Cytological effects of platelet-derived growth factor on mitochondrial ultrastructure in fibroblasts. Comp Biochem Physiol A 128:241–249
22. Greenamyre JT, Betarbet R, Sherer TB (2003) The rotenone model of Parkinson’s disease: genes, environment and mitochondria Parkinsonism. Relat Disord 9(Suppl 2):S59–S64
23. Greenamyre JT, Cannon JR, Drolet R, Mastroberardino PG (2010) Lessons from the rotenone model of Parkinson’s disease. Trends Pharmacol Sci 31:141–142; author reply 142–143. doi:10.1016/j.tips.2009.12.006
24. Gyulkhandanyan AV, Feeney CJ, Pennefather PS (2003) Modulation of mitochondrial membrane potential and reactive oxygen species production by copper in astrocytes. J Neurochem 87:448–460
25. Hamby ME, Sofroniew MV (2010) Reactive astrocytes as therapeutic targets for CNS disorders. Neurotherapeutics 7:494–506. doi:10.1016/j.nurt.2010.07.003
26. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP (2003) The role of glial reaction and inflammation in Parkinson’s disease. Ann N Y Acad Sci 991:214–228
27. Hoglinger GU et al (2005) The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem 95:930–939. doi:10.1111/j.1471-4159.2005.03493.x
28. Iantomasi T, Favilli F, Degl’Innocenti D, Vincenzini MT (1999) Increased glutathione synthesis associated with platelet-derived growth factor stimulation of NIH3T3 fibroblasts. Biochim Biophys Acta 1452:303–312
29. Krupinski J, Issa R, Bujny T, Slevin M, Kumar P, Kumar S, Kaluza J (1997) A putative role for platelet-derived growth factor in angiogenesis and neuroprotection after ischemic stroke in humans Stroke 28:564–573
30. Lee S et al (1997) Early induction of mRNA for calbindin-D28k and BDNF but not NT-3 in rat hippocampus after kainic acid treatment. Brain Res Mol Brain Res 47:183–194
31. Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA, Giese NA (2002) Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 62:3729–3735
32. Mattson MP, Goodman Y, Luo H, Fu W, Furukawa K (1997) Activation of NF-kappaB protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration. J Neurosci Res 49:681–697. doi:10.1002/(SICI)1097-4547(19970915)49:6<681:AID-JNR3>3.0.CO;2-3
33. Ogawa N, Asanuma M, Miyazaki I, Diaz-Corrales FJ, Miyoshi K (2005) L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson’s disease. J Neurol 252(Suppl 4):IV23–IV31. doi:10.1007/s00415-005-4006-7
34. Oliva CR, Moellering DR, Gillespie GY, Griguer CE (2011) Acquisition of chemoresistance in gliomas is associated with increased mitochondrial coupling and decreased ROS production. PLoS ONE 6:e24665. doi:10.1371/journal.pone.0024665PONE-D-11-14137
35. Peng F, Yao H, Akturk HK, Buch S (2012) Platelet-derived growth factor CC-mediated neuroprotection against HIV Tat involves TRPC-mediated inactivation of GSK 3beta. PLoS ONE 7:e47572. doi:10.1371/journal.pone.0047572PONE-D-12-19628
36. Perier C, Vila M (2012) Mitochondrial biology and Parkinson’s disease. Cold Spring Harb Perspect Med 2:a009332. doi:10.1101/cshperspect.a009332a009332
37. Potapova O, Fakhrai H, Mercola D (1996) Growth factor PDGF-B/v-sis confers a tumorigenic phenotype to human tumor cells bearing PDGF receptors but not to cells devoid of receptors: evidence for an autocrine, but not a paracrine, mechanism. Int J Cancer 66:669–677. doi:10.1002/(SICI)1097-021519960529
38. Rappold PM, Tieu K (2010) Astrocytes and therapeutics for Parkinson’s disease. Neurotherapeutics 7:413–423. doi:10.1016/j.nurt.2010.07.001
39. Ruusala A, Sundberg C, Arvidsson AK, Rupp-Thuresson E, Heldin CH, Claesson-Welsh L (1998) Platelet-derived growth factor (PDGF)-induced actin rearrangement is deregulated in cells expressing a mutant Y778F PDGF beta-receptor. J Cell Sci 111(Pt 1):111–120
40. Safi R, Gardaneh M, Panahi Y, Maghsoudi N, Zaefizadeh M, Gharib E (2012) Optimized quantities of GDNF overexpressed by engineered astrocytes are critical for protection of neuroblastoma cells against 6-OHDA toxicity. J Mol Neurosci 46:654–665. doi:10.1007/s12031-011-9654-8
41. Sarafian TA, Montes C, Imura T, Qi J, Coppola G, Geschwind DH, Sofroniew MV (2010) Disruption of astrocyte STAT3 signaling decreases mitochondrial function and increases oxidative stress in vitro. PLoS ONE 5:e9532. doi:10.1371/journal.pone.0009532
42. Simpkins JW, Yi KD, Yang SH, Dykens JA (2010) Mitochondrial mechanisms of estrogen neuroprotection. Biochim Biophys Acta 1800:1113–1120. doi:10.1016/j.bbagen.2009.11.013
43. Stein GH (1979) T98G: an anchorage-independent human tumor cell line that exhibits stationary phase G1 arrest in vitro. J Cell Physiol 99:43–54. doi:10.1002/jcp.1040990107
44. Swarnkar S, Singh S, Goswami P, Mathur R, Patro IK, Nath C (2012) Astrocyte activation: a key step in rotenone induced cytotoxicity and DNA damage. Neurochem Res 37:2178–2189. doi:10.1007/s11064-012-0841-y
45. Tang Z et al (2010) Survival effect of PDGF-CC rescues neurons from apoptosis in both brain and retina by regulating GSK3beta phosphorylation. J Exp Med 207:867–880. doi:10.1084/jem.20091704
46. Tanner CM et al (2011) Rotenone, paraquat, and Parkinson’s disease. Environ Health Perspect 119:866–872. doi:10.1289/ehp.1002839
47. Tiwari M, Lopez-Cruzan M, Morgan WW, Herman B (2011) Loss of caspase-2-dependent apoptosis induces autophagy after mitochondrial oxidative stress in primary cultures of young adult cortical neurons. J Biol Chem 286:8493–8506. doi:10.1074/jbc.M110.163824
48. Torrente D, Avila M, Cabezas R, Morales L, Gonzalez J, Samudio I, Barreto GE (2013) Paracrine factors of human mesenchymal stem cells increase wound closure and reduce reactive oxygen species production in a traumatic brain injury in vitro model. Hum Exp Toxicol 33:673–684. doi:10.1177/0960327113509659
49. Tseng HC, Dichter MA (2005) Platelet-derived growth factor-BB pretreatment attenuates excitotoxic death in cultured hippocampal neurons. Neurobiol Dis 19:77–83. doi:10.1016/j.nbd.2004.11.007
50. Valverde GDAD, Madureira de Oliveria D, Barreto G, Bertolino LA, Saraceno E, Capani F, Giraldez LD (2008) Effects of the extract of Anemopaegma mirandum (Catuaba) on Rotenone-induced apoptosis in human neuroblastomas SH-SY5Y cells. Brain Res 1198:188–196. doi:10.1016/j.brainres.2008.01.006
51. Voloboueva LA, Suh SW, Swanson RA, Giffard RG (2007) Inhibition of mitochondrial function in astrocytes: implications for neuroprotection. J Neurochem 102:1383–1394. doi:10.1111/j.1471-4159.2007.4634.x
52. Volterra A, Meldolesi J (2005) Astrocytes, from brain glue to communication elements: the revolution continues. Nat Rev Neurosci 6:626–640. doi:10.1038/nrn1722
53. Wang HL et al (2011) PARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons. Biochim Biophys Acta 1812:674–684. doi:10.1016/j.bbadis.2011.03.007
54. Watabe M, Nakaki T (2004) Rotenone induces apoptosis via activation of bad in human dopaminergic SH-SY5Y cells. J Pharmacol Exp Ther 311:948–953. doi:10.1124/jpet.104.071381jpet.104.071381
55. Xiong J, Dai W, Chen L, Liu G, Liu M, Zhang Z, Xiao H (2006) New method for studying the relationship between morphological parameters and cell viability. In: Proceedings of SPIE. doi:10.1117/12.676524
56. Zheng L et al (2010) Neuroprotective effects of PDGF against oxidative stress and the signaling pathway involved. J Neurosci Res 88:1273–1284. doi:10.1002/jnr.22302
57. Zhu X, Yao H, Peng F, Callen S, Buch S (2009) PDGF-mediated protection of SH-SY5Y cells against Tat toxin involves regulation of extracellular glutamate and intracellular calcium. Toxicol Appl Pharmacol 240:286–291. doi:10.1016/j.taap.2009.06.020